News

ATCC Hires New Chief Commercial Officer

ATCC, the world’s premier biological materials management and standards organization, today announced it has hired Greg Ballish as its new Chief Commercial Officer. In his role, Ballish will head ATCC’s sales and marketing operations and partner with Ruth Cheng, Ph.D., Chief Innovation and Strategy Officer and Vice President of Corporate Development of ATCC, to oversee the corporate business and commercial center. As part of the executive leadership team, Ballish will focus on growing the company’s global footprint and reinforcing ATCC’s position as the de facto leader in biological resources.

“We are fortunate to add Greg’s considerable experience and inclusive management style to our executive team, and we look forward to seeing the impact of his commercial leadership,” said Raymond H. Cypess, DVM, Ph.D., Chairman and CEO of ATCC. “In his role, Greg will ensure that we remain a customer-centric organization and continue our commitment to exceeding expectations and fostering long-lasting partnerships with the institutions and organizations we serve.”

Ballish brings an extensive sales, marketing and operations background in the diagnostics, pharmaceuticals, medical devices, transfusion medicine and medical distribution markets to ATCC. He has guided organizations to top market share positions and held key leadership sales and marketing roles for companies including Abbott Labs, DuPont, Johnson & Johnson, LabCorp, LGC Clinical Diagnostics, Meridian Bioscience, Terumo BCT and the American Red Cross. Ballish holds a Master of Business Administration from Arizona State University and a Bachelor of Science in finance from Miami University.

Recent News

03/02/2026

Learn about Fairfax FIRST

The Fairfax Innovation for Research, Science, and Technology (FIRST) program is intended to provide participants with the physical address needed for funding applications, while alleviating the financial burden of a lease before substantial funding is received. FIRST supports early-stage entities that seek to advance the development or application of emerging technologies. Acceptance into the program

02/25/2026

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to treating MASH, obesity, and associated cardiometabolic diseases, today announced the appointment of Jorge Bartolome as Chief Executive Officer and member of the Board. He succeeds Allen Cunningham, a co-founder who will move to the role of Chief Operating Officer. Mr. Bartolome has over 25 years of

02/24/2026

Jeeva Clinical Trials Calls on Global Life Sciences Leaders to Modernize Infrastructure for AI-Driven Drug Development

Jeeva Clinical Trials today amplified its call to action for the global pharmaceutical and clinical research ecosystem: Artificial Intelligence will not transform drug development unless organizations modernize the IT infrastructure beneath it. The message — first articulated in a recent thought leadership article by Founder and CEO Harsha K. Rajasimha — has gained strong traction